AbbVie scores key EU backing for Hepatitis C drug in push for earlier treatment
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
Subscribe To Our Newsletter & Stay Updated